Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume 8, Issue 2, Pages 135-149
Publisher
Informa UK Limited
Online
2012-01-30
DOI
10.1586/eci.11.93
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
- (2017) Noel G. Faux et al. JOURNAL OF ALZHEIMERS DISEASE
- EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
- (2012) B. Vellas et al. Current Alzheimer Research
- Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab
- (2011) Christopher Carlson et al. Alzheimers & Dementia
- 2011 Alzheimer’s disease facts and figures
- (2011) Alzheimers & Dementia
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads
- (2011) Francesco Panza et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Solanezumab for Alzheimer's disease
- (2011) Hossein Samadi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Antibody-based therapy in Alzheimer's disease
- (2011) Refik Pul et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
- (2011) Bruno P Imbimbo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
- (2011) Susann Cattepoel et al. PLoS One
- Soluble amyloid -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration
- (2011) M. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease
- (2010) Ronald S. Black et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- Characterization of amino-terminally truncated Abeta-42 peptides in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment
- (2010) Ronald B. DeMattos et al. Alzheimers & Dementia
- Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study
- (2010) Taro Goto et al. Alzheimers & Dementia
- The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia
- (2010) Jessica M. Mc Donald et al. BRAIN
- Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
- (2010) Eric R. Siemers et al. CLINICAL NEUROPHARMACOLOGY
- Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid
- (2010) V. Frisardi et al. Current Alzheimer Research
- Bapineuzumab
- (2010) Geoffrey A Kerchner et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease
- (2010) Francesco Panza et al. Immunotherapy
- Immunotherapy for Alzheimer’s disease
- (2010) D. Morgan JOURNAL OF INTERNAL MEDICINE
- Revising the definition of Alzheimer's disease: a new lexicon
- (2010) Bruno Dubois et al. LANCET NEUROLOGY
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- Alzheimer's disease: clinical trials and drug development
- (2010) Francesca Mangialasche et al. LANCET NEUROLOGY
- Can Alzheimer disease be prevented by amyloid-β immunotherapy?
- (2010) Cynthia A. Lemere et al. Nature Reviews Neurology
- Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment
- (2009) Ronald B. DeMattos et al. Alzheimers & Dementia
- Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo
- (2009) Ryan J. Watts et al. Alzheimers & Dementia
- A γ-secretase inhibitor decreases amyloid-β production in the central nervous system
- (2009) Randall J. Bateman et al. ANNALS OF NEUROLOGY
- Quantitative and Mechanistic Studies of Aβ Immunotherapy
- (2009) Todd Golde et al. CNS & Neurological Disorders-Drug Targets
- Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease
- (2009) Francesco Panza et al. DRUGS & AGING
- Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?
- (2009) Gregory A Jicha EXPERT OPINION ON BIOLOGICAL THERAPY
- A Immunotherapy: Intracerebral Sequestration of A by an Anti-A Monoclonal Antibody 266 with High Affinity to Soluble A
- (2009) K. Yamada et al. JOURNAL OF NEUROSCIENCE
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
- (2009) M. Britschgi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vaccination in the elderly: an immunological perspective
- (2009) Wilbur H. Chen et al. TRENDS IN IMMUNOLOGY
- S1-02-02: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin
- (2008) Norman R. Relkin Alzheimers & Dementia
- P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
- (2008) Eric R. Siemers et al. Alzheimers & Dementia
- Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
- (2008) Dennis J. Selkoe BEHAVIOURAL BRAIN RESEARCH
- Immunotherapy Reduces Vascular Amyloid- in PDAPP Mice
- (2008) S. Schroeter et al. JOURNAL OF NEUROSCIENCE
- Amyloid Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization
- (2008) I. Klyubin et al. JOURNAL OF NEUROSCIENCE
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
- (2008) Lars Lannfelt et al. LANCET NEUROLOGY
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
- (2008) Ganesh M Shankar et al. NATURE MEDICINE
- 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
- (2008) Norman R. Relkin et al. NEUROBIOLOGY OF AGING
- Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
- (2008) Peter Seubert et al. Neurodegenerative Diseases
- Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
- (2008) Scott A. Small et al. NEURON
- Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools
- (2007) Peter Lichtlen et al. JOURNAL OF NEUROCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More